2071209-49-7
Chemical Structure
CAD031
- CAS No.: 2071209-49-7
- Formula:C18H14F6N2O2
- Molecular Weight:404.31
IUPAC Name: (E)-N-(2,4-dimethylphenyl)-2,2,2-trifluoro-N'-(3-(trifluoromethoxy)benzylidene)acetohydrazide
InChIKey: VDYRRQYRYZTLJV-KIBLKLHPSA-N
SMILES: O=C(N(C1=CC=C(C)C=C1C)/N=C/C2=CC=CC(OC(F)(F)F)=C2)C(F)(F)F
Biological Activity: CAD031 is an orally active AMPK/ACC1 signaling pathway activator and a derivative of the Alzheimer's disease (AD) targeted agent J147 (HY-13779) (more active than J147 in human neural stem cell assays). CAD031 can cross the blood-brain barrier, activate AMPK and inhibit ACC1, thereby increasing ac-CoA levels, improving mitochondrial function and reducing free fatty acid synthesis. CAD031 has neuroprotective, neurogenesis-promoting and memory-improving activities and can be used in the study of Alzheimer's disease and aging-related neurodegenerative diseases. CAD031 effectively enhances the memory of mice, improves dendritic structure, and stimulates cell division in the germinal zone of the brain of elderly mice[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CAD031 | 99.39% | CAD031 is an orally active AMPK/ACC1 signaling pathway activator and a derivative of the Alzheimer's disease (AD) targeted agent J147 (HY-13779) (more active than J147 in human neural stem cell assays). CAD031 can cross the blood-brain barrier, activate AMPK and inhibit ACC1, thereby increasing ac-CoA levels, improving mitochondrial function and reducing free fatty acid synthesis. CAD031 has neuroprotective, neurogenesis-promoting and memory-improving activities and can be used in the study of Alzheimer's disease and aging-related neurodegenerative diseases. CAD031 effectively enhances the memory of mice, improves dendritic structure, and stimulates cell division in the germinal zone of the brain of elderly mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Prior M, et al. Selecting for neurogenic potential as an alternative for Alzheimer's disease drug discovery. Alzheimers Dement. 2016 Jun;12(6):678-86. [Content Brief]
- [2]. Currais A, et al. A chemical biology approach to identifying molecular pathways associated with aging. Geroscience. 2021 Feb;43(1):353-365. [Content Brief]
- [3]. Kepchia D, et al. The Alzheimer's disease drug candidate J147 decreases blood plasma fatty acid levels via modulation of AMPK/ACC1 signaling in the liver. Biomed Pharmacother. 2022 Mar;147:112648. [Content Brief]
Keywords
